Zacks Investment Research·1 day ago
Boston Scientific (BSX) Stock Dips While Market Gains: Key FactsBoston Scientific (BSX) closed at $44.6 in the latest trading session, marking a -1.2% move from the prior day.
Boston Scientific Corporation(BSX)Earnings, Financials & Key Ratios
BSX•NYSE
$45.30
23.4× P/E·Price updated Jul 7, 2026
AboutBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.Show more
- Revenue$20.07B+19.9%
- EBITDA$5.34B+36.8%
- Net Income$2.89B+55.7%
- EPS (Diluted)1.94+55.2%
- Gross Margin69.01%+12.6%
- EBITDA Margin26.6%+14.1%
- Operating Margin19.78%+25.7%
- Net Margin14.38%+29.9%
- ROE12.42%+39.1%
BSX Price & Volume
Boston Scientific Corporation (BSX) stock price & volume — 10-year historical chart
Loading chart...
Aggressive Inorganic Growth Drives Revenue Scale Expansion
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Strong
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Regulatory M&A scrutiny
Key Thesis Takeaways
- Boston Scientific maintains a robust growth trajectory, evidenced by revenue scaling from $3.7 billion in 2023Q4 to $5.2 billion in 2026Q1, largely fueled by a consistent strategy of acquiring external innovation.
- While gross margins have improved to 69.4% as of 2026Q1, the firm's reliance on inorganic expansion has inflated goodwill to $18.5 billion, representing a significant portion of the $44.4 billion asset base.
- Investors should monitor the volatility in free cash flow margins, which contracted to 3.3% in 2026Q1, as the company balances aggressive capital deployment with the need for sustained operational cash conversion.
Verdict Logic
while the company demonstrates strong top-line momentum with 11.6% revenue growth, the high concentration of $18.5 billion in goodwill and volatile cash conversion ratios warrant a cautious approach until organic cash flow stability is proven.
BSX Growth Metrics
Boston Scientific Corporation (BSX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.38%
5 Years15.16%
3 Years16.54%
TTM17.44%
Profit CAGR
10 Years-
5 Years-
3 Years60.5%
TTM74.77%
EPS CAGR
10 Years-
5 Years-
3 Years63.25%
TTM74.38%
Return on Capital
10 Years8.19%
5 Years8.06%
3 Years8.97%
Last Year11.15%
BSX Recent Earnings
Boston Scientific Corporation (BSX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 12/12 qtrs (100%)
Q2 2026Latest
Apr 22, 2026Metric
Actual
Est
EPS
$0.80+1.5%
$0.79
Rev
$5.2B+0.6%
$5.2B
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$0.80+2.4%
$0.78
Rev
$5.3B+0.1%
$5.3B
Q4 2025
Oct 22, 2025Metric
Actual
Est
EPS
$0.75+5.0%
$0.71
Rev
$5.1B+1.9%
$5.0B
Q3 2025
Jul 23, 2025Metric
Actual
Est
EPS
$0.75+3.4%
$0.72
Rev
$5.1B+3.4%
$4.9B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 22, 2026 | $0.80vs $0.79+1.5% | $5.2Bvs $5.2B+0.6% |
| Q1 2026 | Feb 4, 2026 | $0.80vs $0.78+2.4% | $5.3Bvs $5.3B+0.1% |
| Q4 2025 | Oct 22, 2025 | $0.75vs $0.71+5.0% | $5.1Bvs $5.0B+1.9% |
| Q3 2025 | Jul 23, 2025 | $0.75vs $0.72+3.4% | $5.1Bvs $4.9B+3.4% |
Based on last 12 quarters of dataView full earnings history →
Latest BSX News
Recent stock market news and headlines for Boston Scientific Corporation (BSX)
Seeking Alpha·1 day ago
Boston Scientific: The Time Has Come To Catch This Falling KnifeRelative to its all-time high of $109.50 reached in September 2025, Boston Scientific Corporation's share price has declined by almost 60% to trade at around $45.00 per share. To put my money where my mouth is, I purchased my last shares on June 30th at an average price of $42.83. My overall purchase price now stands at $45.52. As part of its Q1-26 earnings, Boston Scientific announced a significant outlook revision, reducing its organic growth guidance for fiscal 2026 to a range between 6.5% and 8.0%.
Zacks Investment Research·Jun 30, 2026
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to NoteIn the most recent trading session, Boston Scientific (BSX) closed at $42.68, indicating a -1.84% shift from the previous trading day.
Seeking Alpha·Jun 25, 2026
Boston Scientific's Fall From Penthouse To Doghouse Creates A Value OpportunityBoston Scientific has suffered a 50% share price decline amid decelerating growth and competitive threats, but fundamentals-based valuation now appears attractive. Growth in key segments like electrophysiology and Watchman has slowed due to increased competition, reimbursement cuts, and less impressive clinical trial data. Management now guides to sub-10% revenue growth (6.5%-8% for the year), but I still expect 7.5% annualized growth over five years and improving margins.
Zacks Investment Research·Jun 24, 2026
Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to NoteIn the most recent trading session, Boston Scientific (BSX) closed at $44.46, indicating a -2.5% shift from the previous trading day.
Peers Comparison
Key metrics vs top competitors for Boston Scientific Corporation (BSX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $45.30 | $67.33B | 23.35 | 19.87% | 14.38% | 12.42% | — | |
| $83.83 | $107.63B | 22.47 | 8.43% | 13.2% | 9.78% | — | |
| $94.82 | $54.6B | 51.81 | 11.55% | 17.34% | 10.54% | — | |
| $313.38 | $120.14B | 37.31 | 11.16% | 13.21% | 15.1% | — | |
| $89.41 | $17.51B | 25.19 | 7.2% | 9.05% | 5.77% | — | |
| $156.30 | $56.63B | 26.81 | 8.23% | 5.33% | 4.54% | — |
Compare BSX vs Peers
Boston Scientific Corporation (BSX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BSX SEC Filings & Documents
Boston Scientific Corporation (BSX) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 18, 2026·SEC
Material company update
May 5, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
5Get notified when BSX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BSX Frequently Asked Questions
Boston Scientific Corporation (BSX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Boston Scientific Corporation's revenue?
Boston Scientific Corporation (BSX) reported $20.61B in revenue for fiscal year 2025. This represents a 1310% increase from $1.46B in 1996.
How fast is Boston Scientific Corporation growing?
Boston Scientific Corporation (BSX) grew revenue by 19.9% over the past year. This is strong growth.
Is BSX profitable?
Yes, Boston Scientific Corporation (BSX) is profitable, generating $3.55B in net income for fiscal year 2025 (14.4% net margin).
Dividend & Returns
What is BSX's return on equity?
Boston Scientific Corporation (BSX) has a return on equity (ROE) of 12.4%. This is reasonable for most industries.
What is Boston Scientific Corporation's free cash flow?
Boston Scientific Corporation (BSX) generated $3.44B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.